|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | N/A | Storage (From the date of receipt) |
3 years-20°C powder | |||
| 化学式 | C14H21N3O.2HCl |
||||||
| 分子量 | 320.26 | CAS No. | 129830-38-2 | ||||
| Solubility (25°C)* | 体外 | DMSO (warmed with 50ºC water bath) | 64 mg/mL (199.83 mM) | ||||
| Water | 64 mg/mL (199.83 mM) | ||||||
| Ethanol | 11 mg/mL (34.34 mM) | ||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||
| 製品説明 | Y-27632 2HCl は選択的 ROCK1 (p160ROCK) 阻害剤であり、cell-free assay における Ki は 140 nM です。PKC, cAMP-依存性プロテインキナーゼ, MLCK や PAK など他のキナーゼよりも ROCK1 に対して 200 倍以上の選択性を示します。 |
|---|---|
| in vitro | Y-27632 2HCl inhibits ROCK-II while displaying little activity against PKC, cAMP-dependent protein kinase and myosin light-chain kinase (MLCK) with Ki of 26 μM, 25 μM and > 250 μM, respectively, as well as PKA activated by another Rho-family GTPase member, Cdc42. This compound inhibits smooth-muscle contraction induces by various agonists including phenylephrine, histamine, acetylcholine, serotonin, endothelin, and thromboxane with IC50 of 0.3-1 μM, by selectively inhibiting Ca2+ sensitization. It suppresses Rho-induced, p160ROCK-mediated formation of stress fibres in cultured cells. [1] This chemical treatment blocks both Rho-mediated activation of actomyosin and LPA-stimulated invasive activity of MM1 cells in a concentration-dependent manner. [2] This compound treatment is not only sufficient to initiate formation of exuberant axonal processes but also facilitates axonal maturation during the very early stages of axonogenesis, while largely sparing axon elongation. [3] In human embryonic stem (hES) cells, this chemical treatment at 10 μM markedly diminishes dissociation-induced apoptosis even in serum-free suspension (SFEB) culture, increases cloning efficiency (from ~1% to ~27%), facilitates subcloning after gene transfer, and enables SFEB-cultured hES cells to survive and differentiate into Bf1+ cortical and basal telencephalic progenitors. [4] |
| in vivo | Oral administration of Y-27632 2HCl at 30 mg/kg significantly decreases the blood pressure in a dose-dependent manner in spontaneous hypertensive rats, renal hypertensive rats, as well as deoxycorticosterone acetate (DOCA)-salt hypertensive rats. [1] When this compound is continuously administered at a rate of 0.55 μL per hour by implanted pumps for 11 days tumor cell invasion (MM1 cells expressing Val14-RhoA in rats) is significantly delayed. [2] By inhibiting ROCK, this chemical treatment attenuates hypoxia-induced angiogenesis and vascular remodeling in the pulmonary circulation. [5] Pretreatment with this compound has a protective effect against tumor formation in albino mice with Ehrlich ascites carcinoma. [7] |
| キナーゼアッセイ | Phosphorylation reactions | |
|---|---|---|
| The p160ROCK is expressed in COS cells as tagged full-length proteins, and immunoprecipitated by the use of anti-tag antibodies. The p160ROCK (30 ng) is incubated with 40 μM [γ-32P]ATP (3.3 Ci/mmol) and with 3 μg of either histone (HF2A), dephosphorylated casein or MBP in the presence of various concentrations of this compound at 30 °C in a total volume of 31 μL. A 7 μL aliquot is taken at 0, 5, 10, and 20 minutes, mixed with an equal volume of 2 × Laemmli sample buffer, and applied to SDS-PAGE. The gel is stained with Commassie Blue, dried and subjected to analysis by a Bioimage Analyzer BAS2000. The concentration of this chemical required to inhibit p160ROCK activity by 50% (IC50 value) is obtained. Ki value is calculated according to the equation, Ki = IC50/(1 + S/Km), where S and Km represent concentrations of and Km value for ATP. | ||
| 細胞アッセイ | 細胞株 | hES Cells |
| 濃度 | 10 uM | |
| 反応時間 | 1 h | |
| 実験の流れ | Y-27632 2HCl was added to culture medium at 10 uM 1 h before detaching the cells from the feeder layer and also upon seeding the cells onto a new MEF layer. |
|
| 動物実験 | 動物モデル | Male Wistar rats with spontaneous or induced hypertension; Swiss albino mice with Ehrlich ascites carcinoma |
| 投薬量 | 30 mg/kg/day (Rat); 0-10 mg/kg (mice) | |
| 投与方法 | Orally (Rat); i.p. (Mice) | |
|

Data from [Data independently produced by Mol Neurobiol, 2015, 10.1007/s12035-014-9084-z]

Data from [Data independently produced by J Mol Cell Cardiol, 2014, 67, 49-59]

Data from [Dev Biol, 2012, 370, 33-41]
| SLC7A11 is an unconventional H+ transporter in lysosomes [ Cell, 2025, S0092-8674(25)00406-4] | PubMed: 40280132 |
| A complete model of mouse embryogenesis through organogenesis enabled by chemically induced embryo founder cells [ Cell, 2025, S0092-8674(25)00807-4] | PubMed: 40780195 |
| Subclonal immune evasion in non-small cell lung cancer [ Cancer Cell, 2025, S1535-6108(25)00262-4] | PubMed: 40614739 |
| CellNEST reveals cell-cell relay networks using attention mechanisms on spatial transcriptomics [ Nat Methods, 2025, 22(7):1505-1519] | PubMed: 40481363 |
| LKB1 inactivation promotes epigenetic remodeling-induced lineage plasticity and antiandrogen resistance in prostate cancer [ Cell Res, 2025, 35(1):59-71] | PubMed: 39743630 |
| Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promoters [ Nat Genet, 2025, 57(1):165-179] | PubMed: 39806204 |
| Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promoters [ Nat Genet, 2025, 57(1):165-179] | PubMed: 39806204 |
| HNF1A and A1CF coordinate a beta cell transcription-splicing axis that is disrupted in type 2 diabetes [ Cell Metab, 2025, S1550-4131(25)00334-1] | PubMed: 40774250 |
| A gut-on-a-chip incorporating human faecal samples and peristalsis predicts responses to immune checkpoint inhibitors for melanoma [ Nat Biomed Eng, 2025, 10.1038/s41551-024-01318-z] | PubMed: 39939548 |
| Engineered thoracic spinal cord organoids for transplantation after spinal cord injury [ Nat Biomed Eng, 2025, 10.1038/s41551-025-01549-8] | PubMed: 41136603 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。